February 16, 2017

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We are pleased to inform you that the Company has received USFDA approval for ANDA Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution (Syrup), 5 mg/1.5 mg per 5 mL, Generic of Hycodan® Oral Solution, 5 mg/1.5 mg per 5 mL, of Endo Pharmaceuticals, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**

R. V. SATAM
COMPANY SECRETARY